 |
16 Diseases |  |
3 Trials |
|
3 Trials |  |
5 News |  |
- || Oncopore (ruxotemitide) / Lytix
Clinical, Journal, IO Biomarker: Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report. (Pubmed Central) - Dec 26, 2019
P1
Our patient was treated with repeated intratumoral injections of LTX-315, resulting in tumor regression accompanied by upregulation of immune genes and T-cell infiltration. Local application of immunotherapy, minimizing systemic side effects, represents a novel treatment modality in desmoid tumors that should be tested in further clinical trials.
- Multiferon (interferon alpha) / SOBI
Trial completion, Trial primary completion date: NAM-Trial: Multiferon in Malignant Melanoma (clinicaltrials.gov) - Nov 13, 2014
P2a, N=42, Completed, Sponsor: University Hospital Tuebingen
Local application of immunotherapy, minimizing systemic side effects, represents a novel treatment modality in desmoid tumors that should be tested in further clinical trials. Recruiting --> Completed | Trial primary completion date: Jun 2012 --> Mar 2013
- Multiferon (interferon alpha) / SOBI
New P2 trial: Nordic Study of Multiferon® in Early-Stage Primary Myelofibrosis - a Multicentre Pilot Study (EUDRACT) - Feb 6, 2012
P2, N=20, Ongoing, Sponsor: The Nordic Myeloproliferative Neoplasm Group
- Multiferon (interferon alpha) / SOBI
Enrollment open: NAM-Trial: Multiferon in Malignant Melanoma (clinicaltrials.gov) - Nov 27, 2011
P2a, N=42, Recruiting, Sponsor: University Hospital Tuebingen
Recruiting --> Completed | Trial primary completion date: Jun 2012 --> Mar 2013 Not yet recruiting --> Recruiting
- Rebif (human IFN-β-1a) / EMD Serono, Multiferon (interferon alpha) / SOBI, Betaseron (IFN-β-1b) / Bayer
Trial completion: REPAIR: REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients (clinicaltrials.gov) - Aug 7, 2011
P2, N=10, Completed, Sponsor: Melinda Magyari
Not yet recruiting --> Recruiting Recruiting --> Completed